Dulaglutide
This review examines the available information on dulaglutide, a GLP-1 receptor agonist used for type 2 diabetes management, in the context of breastfeeding safety. The authors note a complete absence of clinical data on dulaglutide use during lactation. They reason that, due to dulaglutide's large molecular weight of approximately 59,669 daltons as a protein molecule, transfer into breast milk is theorized to be minimal. Furthermore, even if trace amounts were present in milk, oral absorption by a nursing infant is considered unlikely because the compound would probably be degraded by proteolytic enzymes in the infant's gastrointestinal tract. Despite this theoretical reassurance, the authors conclude that caution is warranted when considering dulaglutide use during breastfeeding, with heightened concern for newborns and preterm infants, whose gastrointestinal systems may be less capable of fully degrading such compounds. The primary limitation of this review is the total lack of empirical human lactation data, meaning all conclusions are based on pharmacokinetic reasoning and extrapolation rather than direct measurement or clinical observation.
Why this grade: No clinical, animal, or in vitro lactation data are presented; conclusions are based solely on pharmacokinetic reasoning about molecular weight and GI degradation.
No information is available on the clinical use of dulaglutide during breastfeeding. Because dulaglutide is a large protein molecule with a molecular weight of 59,669 daltons, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, dulaglutide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.